ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Entry into a Material Definitive Agreement

Jun 12, 2019 (Market Exclusive via COMTEX) — ACURA PHARMACEUTICALS, INC. ACUR, -10.00% Files An 8-K Entry into a Material Definitive Agreement

About ACURA PHARMACEUTICALS, INC. ACUR, -10.00%

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

The post ACURA PHARMACEUTICALS, INC. ACUR, -10.00% Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

Read More Here...

Bookmark the permalink.